Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C55H85O24.Na |
| Molecular Weight | 1153.2388 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 27 / 27 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[H][C@@]8(O[C@H]1[C@H](O)[C@@H](O[C@]2([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@]([H])(O[C@H]3CC[C@@]4(C)[C@@]([H])(CC[C@]5(C)[C@]4([H])CC=C6[C@]7([H])CC(C)(C)[C@@H](OC(=O)C(\C)=C/C)[C@H](OC(C)=O)[C@]7(CO)[C@H](O)C[C@@]56C)[C@@]3(C)CO)O[C@@H]1C([O-])=O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O
InChI
InChIKey=YFQNXDPEDQNIMQ-RNOOUDSXSA-M
InChI=1S/C55H86O24.Na/c1-10-23(2)46(71)79-43-44(72-24(3)60)55(22-59)26(17-50(43,4)5)25-11-12-30-51(6)15-14-32(52(7,21-58)29(51)13-16-53(30,8)54(25,9)18-31(55)61)75-49-41(77-48-38(67)36(65)34(63)28(20-57)74-48)39(68)40(42(78-49)45(69)70)76-47-37(66)35(64)33(62)27(19-56)73-47;/h10-11,26-44,47-49,56-59,61-68H,12-22H2,1-9H3,(H,69,70);/q;+1/p-1/b23-10-;/t26-,27+,28+,29+,30+,31+,32-,33+,34+,35-,36-,37+,38+,39-,40-,41+,42-,43-,44-,47-,48-,49+,51-,52+,53+,54+,55-;/m0./s1
A-escin (Escin Ia) and isoescin Ia have been traditionally used clinically as the chief active ingredients of escin, a major triterpene saponin isolated from horse chestnut (Aesculus hippocastanum) seeds for the treatment of chronic venous insufficiency, hemorrhoids, inflammation and edema. A-escin administration to prednisolone-treated rats slightly reduced the unfavorable effects of prednisolone on width of periosteal and endosteal osteoid and periosteal transverse growth in the tibia. A-escin suppresses the metastasis of triple-negative breast cancer by inhibiting epithelial-mesenchymal transition via down-regulating LOXL2 expression. Escin Ia has being shown to inhibit pancreatic lipase.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Q9Y4K0 Gene ID: 4017.0 Gene Symbol: LOXL2 Target Organism: Homo sapiens (Human) |
|||
Target ID: CHEMBL2366517 |
35.0 µM [IC50] | ||
Target ID: P00591 Gene ID: NA Gene Symbol: PNLIP Target Organism: Sus scrofa (Pig) |
|||
Target ID: CHEMBL2366517 |
50.0 µM [IC50] | ||
Target ID: P00591 Gene ID: NA Gene Symbol: PNLIP Target Organism: Sus scrofa (Pig) |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Secondary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Substances contained in horse-chestnut seeds. 8. The acylaglycones of cryptoescin and alpha-escin]. | 1970 Sep |
|
| Influence of alpha-escin on the femoral bone strength in ovariectomized rats. | 1999 Nov-Dec |
|
| Effects of alpha-escin on histomorphometrical parameters of long bones in rats with experimental post-steroid osteopenia. | 2000 Jan-Feb |
|
| Anti-obesity effects of escins extracted from the seeds of Aesculus turbinata BLUME (Hippocastanaceae). | 2008 Jan |
|
| A liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of escin Ia and escin Ib in human plasma: application to a pharmacokinetic study after intravenous administration. | 2010 Dec |
|
| Comparative pharmacokinetics and the bioavailability of escin Ib and isoescin Ib following the administration of escin, pure escin Ib and isoescin Ib in rats. | 2014 Feb 3 |
|
| Escin Ia suppresses the metastasis of triple-negative breast cancer by inhibiting epithelial-mesenchymal transition via down-regulating LOXL2 expression. | 2016 Apr 26 |
Sample Use Guides
Mice: Gastric emptying (GE) inhibition by b-escin (escin Ib) (25 mg/kg, p.o.) was attenuated after pretreatment with a single bolus of DL-alpha-methyl-p-tyrosine methyl ester
Route of Administration:
Oral
In human saphenous veins in vitro, venotonic
properties were well confirmed with purified β-aescin. Achieved contractures are maximal at concentrations of 10(−3) M but are already quite evident at
10(−6)–10(−7) M. Aescin, at concentrations
of 10(−3 M) or lower resulted in a clear increase of
contractility in human isolated saphenous veins.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
92135627
Created by
admin on Fri Dec 15 15:17:03 UTC 2023 , Edited by admin on Fri Dec 15 15:17:03 UTC 2023
|
PRIMARY | |||
|
2B56HTU5MJ
Created by
admin on Fri Dec 15 15:17:03 UTC 2023 , Edited by admin on Fri Dec 15 15:17:03 UTC 2023
|
PRIMARY |
SUBSTANCE RECORD
